2022
DOI: 10.1016/j.tube.2022.102186
|View full text |Cite
|
Sign up to set email alerts
|

Enhanced immunogenicity of the tuberculosis subunit Rv0572c vaccine delivered in DMT liposome adjuvant as a BCG-booster

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
1
0
3

Year Published

2022
2022
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(4 citation statements)
references
References 50 publications
0
1
0
3
Order By: Relevance
“…When IC31 is administered in combination with H4 antigen, a robust H4-specific IFN-g response is induced at roughly two weeks post-injection (74). Meanwhile, administration of the liposome adjuvant dimethyldioctadecylammonium/monophosphoryl lipid A/ trehalose 6,6′-dibehenate (DMT) with the rRv0572c protein antigen has been shown to enhance BCG immunogenicity to prevent LBTI reactivation (75). Furthermore, a gadoteridol-loaded cationic adjuvant formulation 01(CAF01)-adjuvanted H1 vaccine has been shown to generate significant antigen-specific T-cell responses that were still detectable after three years, thus demonstrating that long-lasting immunological memory against Mtb can be established in vaccine recipients (25).…”
Section: Novel Tb Vaccine Challenges and Opportunitiesmentioning
confidence: 99%
“…When IC31 is administered in combination with H4 antigen, a robust H4-specific IFN-g response is induced at roughly two weeks post-injection (74). Meanwhile, administration of the liposome adjuvant dimethyldioctadecylammonium/monophosphoryl lipid A/ trehalose 6,6′-dibehenate (DMT) with the rRv0572c protein antigen has been shown to enhance BCG immunogenicity to prevent LBTI reactivation (75). Furthermore, a gadoteridol-loaded cationic adjuvant formulation 01(CAF01)-adjuvanted H1 vaccine has been shown to generate significant antigen-specific T-cell responses that were still detectable after three years, thus demonstrating that long-lasting immunological memory against Mtb can be established in vaccine recipients (25).…”
Section: Novel Tb Vaccine Challenges and Opportunitiesmentioning
confidence: 99%
“…Baru-baru ini, beberapa vaksin TB baru telah dikembangkan baik dalam uji klinis maupun studi praklinis, yang terutama dirancang sebagai vaksin profilaksis dan digunakan untuk pemberian sebelum pajanan. Dalam kebanyakan kasus, vaksin didasarkan pada antigen target yang dikenali oleh sistem kekebalan tubuh selama tahap awal infeksi TB , yang tidak dapat secara efektif mencegah pembentukan dormansi dan resusitasi M. tuberculosis (Mao et al, 2022).…”
Section: Hubungan Faktor Imunisasi Bcg Pada Anak Dengan Kejadian Tube...unclassified
“…Dalam beberapa penelitian telah mengungkapkan bahwa induksi imunitas humoral harus diakui sebagai pilihan untuk pengembangan vaksin TB karena titer antibodi IgA terhadap beberapa antigen M. tuberculosis menunjukkan perlindungan terhadap M. tuberculosis. DMT ajuvan liposom, yang mengandung dimethyldioctadecylammonium (DDA), monophosphoryl lipid A (MPLA), dan trehalose-6, 6′-dibehenate (TDB), telah ditemukan untuk meningkatkan jumlah sel CD8 + T spesifik antigen sambil memunculkan humoral terbatas (Mao et al, 2022) Vaksin BCG merupakan vaksin hidup yang dilemahkan yang berasal dari Mycobacterium bovis dan pertama kali digunakan pada tahun 1921. Kemoterapi dan BCG telah banyak digunakan untuk mengobati dan mencegah TB.…”
Section: Hubungan Faktor Imunisasi Bcg Pada Anak Dengan Kejadian Tube...unclassified
See 1 more Smart Citation